×
Trevena Total Liabilities 2012-2024 | TRVN
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Trevena total liabilities from 2012 to 2024. Total liabilities can be defined as the total value of all possible claims against the corporation.
View More
Trevena Total Liabilities 2012-2024 | TRVN
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Trevena total liabilities from 2012 to 2024. Total liabilities can be defined as the total value of all possible claims against the corporation.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$145.5B
Vertex Pharmaceuticals (VRTX)
$119.4B
Gilead Sciences (GILD)
$114.5B
Bristol Myers Squibb (BMY)
$113.1B
CSL (CSLLY)
$84.9B
Regeneron Pharmaceuticals (REGN)
$80.4B
GSK (GSK)
$70.4B
Argenex SE (ARGX)
$36.7B
Alnylam Pharmaceuticals (ALNY)
$31.7B
BioNTech SE (BNTX)
$28.6B
Illumina (ILMN)
$22.8B
Biogen (BIIB)
$21.9B
BeiGene (BGNE)
$17.5B
Moderna (MRNA)
$16.1B
Genmab (GMAB)
$13.3B
Incyte (INCY)
$13.2B
Insmed (INSM)
$12.8B
BioMarin Pharmaceutical (BMRN)
$12.6B
Bio-Techne Corp (TECH)
$12B
Sarepta Therapeutics (SRPT)
$11.8B
Exact Sciences (EXAS)
$11.3B
Vaxcyte (PCVX)
$10.9B
QIAGEN (QGEN)
$10.4B
Exelixis (EXEL)
$10B
Bio-Rad Laboratories (BIO.B)
$9.4B
Intra-Cellular Therapies (ITCI)
$8.8B
Repligen (RGEN)
$8.8B
Roivant Sciences (ROIV)
$8.6B
Ascendis Pharma (ASND)
$7.9B
Revolution Medicines (RVMD)
$7.6B